As price pressure mounts, pharma companies tap analytics to cut costs

Cipla is the first company in the Asia Pacific to upgrade to a cloud-based pharmacovigilance solution

Pharmaceutical companies, on account of price pressures and an intense regulatory gaze, are investing in data analytics and digital tools to sharpen their marketing focus and improve compliance. 

The move comes in the backdrop of price competitiveness in key markets and regulatory actions leading to adverse audit observations and warning letters.

“Businesses that digitalise will have a huge competitive advantage over others. At Cipla we are leveraging new-age technologies to drive efficiencies,” said Kedar Upadhye, Cipla's global chief financial officer.

The drugmaker has implemented manufacturing-execution systems to provide real-time feedback, automate material flows, capture cost information, and drive a paperless workflow, which reduces